Hematology/Oncology

Top Story

Surge in FDA-approved myeloma agents brings new therapeutic decision challenges

Surge in FDA-approved myeloma agents brings new therapeutic decision challenges
May 6, 2016

With a record number of FDA approvals granted for multiple myeloma drugs in the past year, the field is buoyed by the range of treatment options that stand to enhance survival and improve quality of life for patients.

However, the rapidly-expanding therapeutic armamentarium also carries complexities in selecting, combining and sequencing agents — leaving clinicians with a new set of decisions to optimize and personalize care.

Meeting News Coverage

Clinically diagnosed tumors linked to improvements in cancer-specific survival

May 6, 2016
A clinical diagnosis of early-stage lung cancer was associated with improvements in cancer-specific survival compared with only receiving a pathological diagnosis…
Meeting News Coverage

Hyperglycemia increases infection risk in older patients with AML

May 6, 2016
Hyperglycemia appears common in patients aged older than 65 years with acute myeloid leukemia and increased risk for infection, according to results of a retrospective…
In the Journals

Landmark prostate cancer screening trial may have misrepresented data

May 5, 2016
The rates of PSA screening reported in the control group of the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial may have been inaccurately reported…

Henry Ford Health System program director named Komen Scholar

May 5, 2016
Lisa A. Newman, MD, MPH, director of the breast cancer program at Henry Ford Health System, has been selected to serve as a Komen Scholar for a 3-year term.Komen…
More News Headlines »
CME

The Patient with Multiple Ecchymoses

No commercial support for this activity.

Glanzmann’s thrombasthenia is a rare, inherited bleeding disorder that results from a mutation in αIIbß3, an integrin…
More »
Video
At Issue

VIDEO: Progress in MRD testing poised to further improve patient outcomes in myeloma

May 3, 2016
More »
Featured
CME

Optimizing the Use of Targeted Therapy in Advanced Melanoma: Where We Are and Where We Are Going

This activity is supported by an educational grant from Genentech.

Melanoma is the deadliest form of skin cancer. Historically, treatment options have been limited for patients with…
More »
Current Issues
View the Current Issue
HemOnc Today
morganatic-roan